Cargando…
Post first-line dacarbazine or temozolomide in neuroendocrine carcinoma
OBJECTIVE: First-line chemotherapy in metastatic neuroendocrine carcinomas (NECs) is based on etoposide and platinum. However, there is no standard concerning second-line treatment. The objective of this study was to evaluate efficacy and tolerance of dacarbazine or temozolomide in metastatic digest...
Autores principales: | Couronne, Thomas, Girot, Paul, Hadoux, Julien, Lecomte, Thierry, Durand, Alice, Fine, Caroline, Vandevoorde, Katia, Lombard-Bohas, Catherine, Walter, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354717/ https://www.ncbi.nlm.nih.gov/pubmed/32380470 http://dx.doi.org/10.1530/EC-20-0192 |
Ejemplares similares
-
Prognostic factors in neuroendocrine carcinoma: biological markers are more useful than histomorphological markers
por: Freis, Patricia, et al.
Publicado: (2017) -
Management of neuroendocrine neoplasms: conformity with guidelines in and outside a center of excellence
por: Morin, Carole, et al.
Publicado: (2022) -
Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas
por: Olsen, Ingrid H., et al.
Publicado: (2012) -
Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms
por: Tafuto, Salvatore, et al.
Publicado: (2019) -
Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study
por: Smith, Denis, et al.
Publicado: (2022)